To analyze the evolution of the Ministry of Health's spending on drugs.
INTRODUCTION
In Brazil, the publication of the Política Nacional de Medicamentos (National Drug Policy) in 1998 a encouraged the creation of programs aimed at guaranteeing the population's access to drugs. If, on the one hand, drug access is fundamental to guarantee the constitutional right to health, on the other, it has become a reason for concern about the evolution of spending. A study performed in 2007 showed irregular growth in spending on health and drugs at the federal level. For the Ministry of Health, while total spending on health increased by 9.6%, those on drugs increased by 123.9%, between 2002 and 2006. b Similar situation has occurred in other countries. In the United Kingdom, spending on drugs in primary care grew 10% between 2001 and 2002 and caused a fi nancial crisis. 3 In Canada, growth in spending was estimated at 6% in 2006, totaling US$ 25 billion, of which US$ 21.1 billion were on prescription drugs. • Pharmaceutical Service Basic Component -aimed at pharmaceutical service materials and drug acquisition in primary health care and those associated with specifi c health programs and problems.
• Pharmaceutical Service Strategic Component -funds pharmaceutical service actions for the following strategic health programs: a) control of endemic diseases, such as tuberculosis, leprosy, malaria, leishmaniasis, Chagas's disease and other endemic diseases with a national or local scope b) AIDS/STD program's ARV drugs; c) blood and blood derivatives; and d) immune-biological vaccines and serums.
• Exceptional Circumstance Distribution Drug Component -aimed at acquisition and distribution of this type of drugs, in accordance with criteria established by the Protocolos Clínicos e Diretrizes Terapêuticas (Therapeutic Directives and Clinical Protocols).
In this context, the present study aimed to analyze the Ministry of Health's evolution of spending on drug programs.
METHODS
Analysis was performed from total (added) spending and its (not added) programs, between 2002 and 2007.
Survey of Federal Budget actions that funded drug acquisition was performed using the Siga Brasil system. d As research universe, the item "Despesa execução" (settled expense) of each year was selected from its corresponding Lei Orçamentária Anual (LOA -Annual Budget Law), such as LOA 2007 -Despesa execução. The universe name, program as code and description, action as code and description, and values settled were defi ned as research "result objects". The "consultation filter" was the "Fundo Nacional de Saúde" (FNS -National Health Fund) budget unit.
Settled values that were constant on the spreadsheet were added to obtain the total value settled by the FNS for each year. In the case of values settled for drug acquisition, all budget actions were identifi ed on each spreadsheet as code and description, whose name is associated with or suggests the offer of treatment to patients, regardless of the category of resource use (whether direct use or transfer to other federal units, foreign locations or private non-profi t institutions).
Coherence among the product defi ned in the LOA e for each action, the objective of the program to which it belongs, and the indicators proposed for each program was observed to confi rm whether budget actions actually funded drug acquisition. Distribution of total spending on drugs in pharmaceutical service programs or actions defi ned in the federal budget is shown on Table 1 . On this Table, In the period analyzed, spending on primary care drugs increased by 75%, and that on strategic program drugs, by 124%. In the case of STD/AIDS drugs, the increase was about 6%. However, the situation of spending on such drugs was peculiar: an increase of 77% between Table 2 shows the share of spending on each antiretroviral drug in each year's total spending on this group of drugs.
RESULTS

Actual
Moreover, Table 2 shows that the majority of these drugs (79%, or 11 of the 14 ARV drugs) had their prices substantially reduced between 2006 and 2007. There was also reduction in the amount acquired for 50% of them. corroborates the increase in drug spending worldwide, especially in the last decade. 1, 3 The US government estimated that spending on drugs would rise from US$ 184 billion in 2003 to US$ 519 billion in 2013. 5 In the case of Brazil, the growth rate between 2002 and 2006 (annual average of 33.6%) was higher than that between 2006 and 2007 (4.4%). This situation could be explained by the fact that only after the Política Nacional de Medicamentos (National Drug Policy) was published in 1998, were programs aimed to guarantee the population's access to drugs either created or expanded. Thus, subsequent years are certainly characterized by rapid growth in resource allocation for the purpose of supplying demand for drugs. As regards the 4.4% growth between 2006 and 2007, it is necessary to wait for the coming years to observe whether this slowing down of growth will continue or not.
The share of spending on drugs in the Ministry of Health's total spending shows the importance that this expense component has assumed throughout the years analyzed. The small reduction observed in 2006 and 2007 is justifi ed by the fact that total resources allocated by the Ministry of Health increased more than the growth in drug spending in 2007, when compared to the previous year.
Even though the share in total spending has decreased, increase in drug spending is a world trend and some factors have already been pointed out to explain this pattern.
1 Table 1 shows that the major contribution to the increase in total spending on drugs in the period analyzed resulted from exceptional circumstance distribution drugs (an increase of 252% between 2003 and 2007). In addition, data confi rm the discrepancy between resources allocated for primary health care drugs and those allocated for medium-and high-complexity health care drugs. In 2007, for example, R$ 319.9 million were allocated in transfers for states and cities to acquire primary care drugs and R$ 2,7 billion in STD/AIDS drugs and those of exceptional circumstance distribution. Even if the Ministry of Health's strategic program drugs (tuberculosis, leprosy, and human insulin) were included in the amount for primary care, the ratio between spending on STD/AIDS and exceptional circumstance distribution drugs and spending on pharmaceutical services in strategic and primary care would be 2.6 reais to 1 real.
However, the scope of these programs needs to be considered. STD/AIDS and exceptional circumstance distribution drugs serve specifi c groups of patients (those with HIV/AIDS and those with chronic and usually rare diseases), while pharmaceutical service drugs in strategic and primary care are aimed at more important diseases from an epidemiological point of view and, consequently, the population as a whole. Major differences between drugs used in these two subgroups of programs make it diffi cult to compare and make conclusions about a possible emphasis on medium-and high-complexity care, to the detriment of primary care. One of them is that an important portion of STD/AIDS and exceptional circumstance distribution drugs are protected by patents, thus causing the cost of these products to be higher.
Studies on factors in the recent trend in ARV drug cost in Brazil showed that those which had been patented The remaining drugs are protected by patents, even though efavirenz, which became subject to compulsory licensing in May 2007, is one of them, thus enabling acquisition of this generic drug internationally.
a In addition, there was no change in therapeutic consensus in this year and, as a result, none of these drugs stopped being/ began to be less used.
Reduction in prices of ARV drugs acquired both in 2006 and 2007 was observed, according to Table 2 As regards exceptional circumstance distribution drugs, the fact that budget values settled between 2003 and 2005 were lower than the values in procedures approved reveals that resources from other budget actions, especially those for drug acquisition, were used to perform payments to State Departments of Health, which was fully achieved in 2002, when there was no specifi c budget action to fund the program (Table 3) . In 2006 and 2007, this relationship reversed and this can be justifi ed by the acquisition of the following drugs by the Ministry of Health, in a centralized manner: imiglucerase 200 UI, epoetin alfa 2,000 and 4,000 UI, human immune-globulin 5 g, interferon alfa-2b 3,000,000, 5,000,000 and 10,000,000 UI.
b In this way, it is possible to observe that these four pharmaceuticals were responsible for 28% of the program's total spending. Table 3, especially The present study does not intend to defend indiscriminate restriction on drug spending. Even though there are no data on the number of people with drug access, values allocated indicate an important increase in the last years, which is relevant for primary care, as long as the resources are adequately used. Information on spending is an essential measure for effi cient management of pharmaceutical services and SUS resources. Grangeiro et al 2 predicted investment in other areas would be compromised, if current rates of ARV drug spending and gross domestic product growth were maintained.
Differences observed on
In conclusion, despite the government's having saved about half of the spending on ARV drug acquisition by negotiation, 6 its role is as important as those of prescribers and patients. The increase in drug spending may be more associated with the number of drugs prescribed for certain age groups/sex and drug type in different therapeutic classes than with the population's demographic changes. 4 This emphasizes the importance of effi cient management of pharmaceutical services and, consequently, of information about drug spending as a process component. 
